CLNN

Clene Inc. NASDAQ

Healthcare ·Biotechnology ·US · clene.com

$8.09

Mkt Cap $80.9M

52w Low $2.28 51.8% of range 52w High $13.50

50d MA $5.70 200d MA $6.20

P/E (TTM) -2.3x

EV/EBITDA -3.4x

P/B —

Debt/Equity -1.2x

ROE 148.8%

P/FCF -3.1x

RSI (14) —

ATR (14) —

Beta 0.62

50d MA $5.70

200d MA $6.20

Avg Volume 77.4K

About

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 12, 2026	AMC	-0.74	-0.88	-18.9%	5.92	+1.4%	-3.4%	+0.7%	+3.5%	+11.0%	-0.8%	+9.5%	—
Nov 13, 2025	AMC	-0.60	-0.85	-41.7%	7.30	-4.0%	+16.7%	+17.9%	+17.3%	+18.5%	+20.0%	-14.5%	—
Aug 14, 2025	AMC	-0.49	-0.78	-59.2%	3.60	-1.9%	+0.6%	+17.8%	+24.4%	+56.1%	+48.3%	+73.6%	—
May 7, 2025	AMC	-1.10	-0.50	+54.5%	2.55	+7.5%	+1.2%	+3.1%	+6.7%	+3.5%	+4.3%	+66.7%	—
Mar 24, 2025	AMC	-1.21	-1.67	-38.0%	3.92	-2.3%	-11.7%	-9.7%	-18.9%	-17.9%	-21.4%	-27.8%	—
Nov 13, 2024	AMC	-1.34	-1.22	+9.0%	4.82	+1.9%	-2.7%	-6.0%	-8.7%	-3.3%	-15.1%	+2.7%	—
Aug 7, 2024	AMC	-1.60	-1.06	+33.8%	4.50	-3.1%	-2.0%	+12.4%	+13.6%	+12.7%	+10.2%	+31.8%	—
May 8, 2024	AMC	-1.80	-1.80	+0.0%	7.80	+1.3%	-0.8%	-0.9%	+0.3%	-1.5%	-1.9%	-4.6%	—
Mar 13, 2024	AMC	-1.40	-1.20	+14.3%	8.79	+0.1%	-4.4%	-9.0%	-7.4%	-8.8%	-9.0%	-18.2%	—
Nov 7, 2023	AMC	-2.00	-0.40	+80.0%	8.40	+7.1%	-1.0%	-4.5%	+7.1%	+11.8%	+4.2%	-3.2%	—
Aug 14, 2023	AMC	-2.60	-2.40	+7.7%	14.50	+1.7%	+2.8%	+0.6%	-2.1%	-2.1%	-4.8%	-16.3%	—
May 12, 2023	AMC	-3.20	-3.00	+6.2%	17.60	+0.0%	+1.7%	+2.3%	+4.5%	+4.5%	+5.6%	+23.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 13	Canaccord Genuity	Maintains	Buy → Buy	—	$5.92	$6.00	+1.4%	-3.4%	+0.7%	+3.5%	+11.0%	-0.8%
Mar 12	D. Boral Capital	Maintains	Buy → Buy	—	$5.58	$5.58	+0.0%	+6.1%	+2.5%	+6.8%	+9.9%	+17.7%
Jan 9	D. Boral Capital	Maintains	Buy → Buy	—	$5.97	$5.97	+0.0%	+7.2%	-13.2%	-14.6%	-14.2%	-14.4%
Dec 10	D. Boral Capital	Maintains	Buy → Buy	—	$6.23	$6.14	-1.4%	+7.2%	+10.4%	+8.7%	+0.2%	+3.2%
Dec 3	D. Boral Capital	Maintains	Buy → Buy	—	$9.26	$9.30	+0.4%	-22.0%	-32.1%	-37.7%	-36.7%	-32.7%
Nov 17	D. Boral Capital	Maintains	Buy → Buy	—	$8.52	$8.38	-1.6%	+1.1%	+0.5%	+1.5%	+2.8%	+8.8%
Sep 25	D. Boral Capital	Maintains	Buy → Buy	—	$6.05	$6.14	+1.5%	-2.8%	-2.8%	-1.0%	-0.3%	+15.2%
Sep 10	Benchmark	Maintains	Buy → Buy	—	$6.60	$6.60	+0.0%	-2.0%	-6.4%	-12.1%	-5.3%	-4.1%
Aug 21	D. Boral Capital	Maintains	Buy → Buy	—	$5.62	$5.50	-2.1%	-5.0%	+0.7%	-5.2%	-4.3%	-4.3%
Aug 18	Canaccord Genuity	Maintains	Buy → Buy	—	$3.62	$3.66	+1.1%	+17.1%	+23.8%	+55.2%	+47.5%	+56.4%
Aug 14	D. Boral Capital	Maintains	Buy → Buy	—	$3.65	$3.52	-3.6%	-1.4%	-0.8%	+16.2%	+22.7%	+54.0%
Jul 18	D. Boral Capital	Maintains	Buy → Buy	—	$3.90	$3.95	+1.3%	-2.1%	-0.8%	-2.3%	-4.1%	-6.2%
Jun 30	D. Boral Capital	Maintains	Buy → Buy	—	$3.76	$3.70	-1.6%	+4.0%	+3.7%	+5.1%	+3.7%	+2.9%
May 8	Benchmark	Maintains	Buy → Buy	—	$2.55	$2.74	+7.5%	+1.2%	+3.1%	+6.7%	+3.5%	+4.3%
May 8	D. Boral Capital	Maintains	Buy → Buy	—	$2.55	$2.74	+7.5%	+1.2%	+3.1%	+6.7%	+3.5%	+4.3%
Apr 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.66	$2.75	+3.4%	+7.5%	+12.8%	+14.3%	+13.9%	+15.8%
Apr 8	D. Boral Capital	Maintains	Buy → Buy	—	$2.66	$2.75	+3.4%	+7.5%	+12.8%	+14.3%	+13.9%	+15.8%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.92	$3.83	-2.3%	-11.7%	-9.7%	-18.9%	-17.9%	-21.4%
Mar 24	D. Boral Capital	Maintains	Buy → Buy	—	$4.14	$4.20	+1.4%	-5.3%	-16.4%	-14.5%	-23.2%	-22.2%
Mar 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.14	$4.20	+1.4%	-5.3%	-16.4%	-14.5%	-23.2%	-22.2%
Mar 12	D. Boral Capital	Maintains	Buy → Buy	—	$4.54	$4.40	-3.1%	-3.1%	-3.7%	-2.4%	+0.4%	-1.8%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.54	$4.40	-3.1%	-3.1%	-3.7%	-2.4%	+0.4%	-1.8%
Feb 25	D. Boral Capital	Maintains	Buy → Buy	—	$4.23	$4.47	+5.7%	+0.9%	+0.9%	+4.5%	+6.4%	+2.4%
Feb 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.23	$4.47	+5.7%	+0.9%	+0.9%	+4.5%	+6.4%	+2.4%
Feb 6	D. Boral Capital	Maintains	Buy → Buy	—	$4.63	$4.61	-0.4%	-4.5%	-5.6%	-1.7%	-1.1%	-0.6%
Dec 19	D. Boral Capital	Maintains	Buy → Buy	—	$4.12	$4.32	+4.9%	+4.4%	+6.8%	+14.6%	+21.4%	+23.3%
Dec 10	D. Boral Capital	Maintains	Buy → Buy	—	$4.75	$4.77	+0.4%	+3.8%	+4.6%	+4.4%	+4.2%	-1.1%
Nov 22	Benchmark	Maintains	Buy → Buy	—	$4.01	$4.02	+0.2%	+4.0%	+1.7%	-3.2%	+3.5%	+4.2%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.82	$4.91	+1.9%	-2.7%	-6.0%	-8.7%	-3.3%	-15.1%
Nov 14	Canaccord Genuity	Maintains	Buy → Buy	—	$4.82	$4.91	+1.9%	-2.7%	-6.0%	-8.7%	-3.3%	-15.1%
Nov 13	D. Boral Capital	Maintains	Buy → Buy	—	$5.30	$5.11	-3.6%	-9.1%	-11.5%	-14.5%	-17.0%	-12.1%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.40	$5.40	+0.0%	-2.4%	-0.9%	+8.7%	+18.1%	+15.6%
Oct 24	EF Hutton	Maintains	Buy → Buy	—	$5.40	$5.40	+0.0%	-2.4%	-0.9%	+8.7%	+18.1%	+15.6%
Oct 4	Canaccord Genuity	Maintains	Buy → Buy	—	$4.95	$5.00	+1.0%	+7.1%	+7.5%	+3.6%	+18.2%	+11.3%
Oct 2	EF Hutton	Maintains	Buy → Buy	—	$4.60	$4.60	+0.0%	+6.3%	+7.6%	+15.2%	+15.7%	+11.5%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.74	$6.70	-0.6%	-17.1%	-21.5%	-25.5%	-23.0%	-25.8%
Sep 16	EF Hutton	Maintains	Buy → Buy	—	$6.74	$6.70	-0.6%	-17.1%	-21.5%	-25.5%	-23.0%	-25.8%
Aug 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.41	$4.42	+0.2%	+14.7%	+15.9%	+15.0%	+12.5%	+10.7%
Aug 6	Canaccord Genuity	Maintains	Buy → Buy	—	$4.00	$4.12	+3.0%	+47.0%	+12.5%	+10.2%	+26.5%	+27.8%
Jun 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.82	$7.78	-0.5%	+1.4%	-2.2%	-7.9%	-10.2%	-5.6%
Jun 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.47	$8.28	+10.8%	+1.7%	+4.7%	+6.2%	+2.4%	-3.6%
May 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.02	$7.25	+3.3%	-3.1%	+5.1%	-2.8%	-6.3%	-10.0%
May 23	Benchmark	Maintains	Buy → Buy	—	$7.28	$7.52	+3.3%	-4.3%	-3.6%	-6.6%	+1.4%	-6.3%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.83	$7.78	-0.6%	-0.4%	-1.1%	-1.3%	-0.1%	-1.9%
Apr 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.20	$7.20	+16.1%	+9.5%	+6.5%	+12.6%	+7.4%	+8.1%
Mar 20	Benchmark	Maintains	Buy → Buy	—	$8.02	$8.02	+0.0%	-0.2%	+6.0%	+10.7%	+7.2%	+5.7%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.88	$9.76	+9.9%	-1.0%	-5.4%	-9.9%	-8.3%	-9.7%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.00	$10.00	+0.0%	-11.0%	-11.2%	-12.1%	-16.0%	-20.0%
Feb 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.99	$9.20	+2.3%	-4.3%	-4.3%	-5.1%	-5.5%	-3.4%
Dec 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.30	$6.76	-34.4%	-38.8%	-43.7%	-46.5%	-49.5%	-45.6%

Recent Filings

8-K · 8.01 !! High

Clene Inc. -- 8-K 8.01: Material Event / Announcement

Clene Inc. received FDA meeting minutes confirming discussions about accelerated approval pathway for its ALS treatment, potentially expediting the company's NDA filing timeline.

May 4

8-K · 1.01 !! High

Unknown — 8-K 1.01: Material Agreement

CLNN retains flexibility to exit its NYU research partnership while protecting proprietary technology, reducing downside risk if the collaboration underperforms or diverts resources from core operations.

Mar 17

8-K

Unknown — 8-K Filing

Clene reported 2025 full-year results and CNM-Au8 updates for its neurodegeneration pipeline; investors should monitor clinical trial progress and cash runway as a pre-revenue biotech.

Mar 12

8-K · 8.01 !! High

Clene Inc. -- 8-K 8.01: Material Event / Announcement

Clene Inc. announced a material event via press release filing, though specific details require reviewing the exhibit to assess impact on shareholders.

Feb 24

Data updated apr 25, 2026 1:43am · Source: massive.com